市場調查報告書
商品編碼
1291620
腎癌治療和診斷市場2023-2028年按成分、癌症類型、應用和地區分類Kidney Cancer Therapeutics and Diagnostics Market by Component, Cancer Types, Application, and Region 2023-2028 |
全球腎癌治療和診斷市場規模在2022年達到47.2億美元。展望未來,IMARC Group預計,到2028年,市場規模將達到71.7億美元,在2023-2028年期間,成長率(CAGR)為7.12%。腎癌發病率的上升,老年人口的增加,以及一些政府的有利計劃代表了推動市場的一些關鍵因素。
腎癌是一種慢性疾病,腎臟組織中出現異常的細胞生長,從而變成腫瘤。其症狀包括血尿、食慾不振、腹痛、疲倦、發燒、體重減輕、骨痛、高血壓和貧血。腎癌可通過各種技術進行診斷,如血液和尿液檢查、活體組織切片、生物標記檢測、電腦斷層掃描(CT)、X光、磁共振成像(MRI)、膀胱鏡和腎臟輸尿管鏡檢查。它可以通過藥物、化療、放療、腎切除、冷凍消融、射頻消融和靶向治療來治療。腎癌治療方法和診斷方法有助於清除癌細胞,摧毀腫瘤和防止複發,並協助醫生規劃治療。它們還有助於改善腎臟功能,減少未來的併發症,控制癌症擴散,並提高病人的舒適度。
由於吸煙習慣、肥胖、遺傳條件和接觸化學品等因素的日益普遍,腎癌的發病率不斷上升,這是推動市場成長的主要因素之一。腎癌治療和診斷方法被廣泛用於分析和治療腎細胞癌(RCC)、良性腎臟腫瘤、威爾姆斯腫瘤、過渡性細胞癌、腎臟肉瘤、髓樣癌、多囊性RCC以及粘液性管狀和紡錘形細胞癌。此外,對腎細胞癌和其他形式的腎癌具有高度敏感性的老年人口的增加,促進了對治療和診斷的需求,以管理腫瘤,延長生存期,並保留腎臟的非癌變部分。此外,最近開發的能夠檢測生物標記的診斷工具,如含有5的桿狀病毒IAP重複(BIRC5),是早期檢測透明細胞RCC和預測病人預後的關鍵指標,正在積極地影響市場的成長。除此之外,引入3D(3D)列印技術來創建腎臟及其腫瘤的術前模型,進而幫助醫生製定治療計劃,為患者提供適當的諮詢,減少手術錯誤,提高效率,並保留大部分腎臟功能,這些都有利於市場的成長。此外,政府實施各種計劃來傳播有關癌症的意識,正在為市場創造一個積極的前景。其他因素,包括醫療保健行業的顯著成長,為確定潛在的治療方案而對研究和開發(R&D)活動的投資增加,以及先進技術的廣泛採用,如機器人手術、遠程醫療和人工智慧(AI),預計將進一步推動市場成長。
請注意,這只代表部分公司的名單,完整的名單已在報告中提供。
The global kidney cancer therapeutics and diagnostics market size reached US$ 4.72 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.17 Billion by 2028, exhibiting a growth rate (CAGR) of 7.12% during 2023-2028. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.
Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.
The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.
IMARC Group provides an analysis of the key trends in each segment of the global kidney cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on component, cancer types, and application.
Drugs
Drugs by Therapeutic Class
Targeted Therapy
Immunotherapy
Others
Drugs by Pharmacologic Class
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (II-2)
Diagnostics
Imaging Test
Biopsy
Blood Test
Others
The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2))) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.
Clear Cell RCC
Papillary RCC
Chromophobe RCC
Transitional Cell Carcinoma
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the cancer types has been provided in the report. This includes clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. According to the report, clear cell RCC accounted for the largest market share.
Hospitals
Pharmaceutical Labs
Genomic Laboratories
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the application has been provided in the report. This includes hospitals, pharmaceutical labs, genomic laboratories, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.